{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:12:19Z","timestamp":1794345139063,"version":"4.9.0"},"reference-count":197,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.kint.2019.02.030","type":"journal-article","created":{"date-parts":[[2019,3,12]],"date-time":"2019-03-12T22:28:05Z","timestamp":1552429685000},"page":"302-319","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":259,"title":["Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis"],"prefix":"10.1016","volume":"96","author":[{"given":"Jonatan","family":"Barrera-Chimal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Girerd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Jaisser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2019.02.030_bib1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1124\/pr.115.011106","article-title":"Emerging roles of the mineralocorticoid receptor in pathology: toward new paradigms in clinical pharmacology","volume":"68","author":"Jaisser","year":"2016","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.kint.2019.02.030_bib2","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1161\/CIRCRESAHA.108.174235","article-title":"Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion","volume":"102","author":"Caprio","year":"2008","journal-title":"Circ Res"},{"key":"10.1016\/j.kint.2019.02.030_bib3","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1681\/ASN.2012111094","article-title":"Myeloid mineralocorticoid receptor activation contributes to progressive kidney disease","volume":"25","author":"Huang","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.02.030_bib4","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1161\/01.HYP.0000154681.38944.9a","article-title":"Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability","volume":"45","author":"Nishiyama","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2019.02.030_bib5","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1161\/01.HYP.0000174593.88899.68","article-title":"Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1\/2 in rat renal fibroblasts","volume":"46","author":"Nagai","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2019.02.030_bib6","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/HYPERTENSIONAHA.109.131110","article-title":"Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone\/salt-induced cardiac fibrosis and increased blood pressure","volume":"54","author":"Rickard","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2019.02.030_bib7","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1172\/JCI41080","article-title":"Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice","volume":"120","author":"Usher","year":"2010","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2019.02.030_bib8","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1161\/CIRCRESAHA.116.310480","article-title":"T-cell mineralocorticoid receptor controls blood pressure by regulating interferon-gamma","volume":"120","author":"Sun","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.kint.2019.02.030_bib9","first-page":"479","article-title":"Parallel determination of mineralocorticoid and glucocorticoid receptors in T- and B-lymphocytes of human spleen","volume":"118","author":"Armanini","year":"1988","journal-title":"Acta Endocrinol (Copenh)"},{"key":"10.1016\/j.kint.2019.02.030_bib10","doi-asserted-by":"crossref","first-page":"F1473","DOI":"10.1152\/ajprenal.00437.2010","article-title":"In\u00a0vivo nuclear translocation of mineralocorticoid and glucocorticoid receptors in rat kidney: differential effect of corticosteroids along the distal tubule","volume":"299","author":"Ackermann","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2019.02.030_bib11","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1096\/fj.09-147926","article-title":"The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure","volume":"24","author":"Nguyen Dinh Cat","year":"2010","journal-title":"FASEB J"},{"key":"10.1016\/j.kint.2019.02.030_bib12","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1161\/01.RES.0000159937.05502.d1","article-title":"Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells","volume":"96","author":"Jaffe","year":"2005","journal-title":"Circ Res"},{"key":"10.1016\/j.kint.2019.02.030_bib13","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1681\/ASN.2005020129","article-title":"Aldosterone stimulates proliferation of mesangial cells by activating mitogen-activated protein kinase 1\/2, cyclin D1, and cyclin A","volume":"16","author":"Terada","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.02.030_bib14","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2567.2007.02611.x","article-title":"Glucocorticoids exert opposing effects on macrophage function dependent on their concentration","volume":"122","author":"Lim","year":"2007","journal-title":"Immunology"},{"key":"10.1016\/j.kint.2019.02.030_bib15","doi-asserted-by":"crossref","first-page":"7605","DOI":"10.4049\/jimmunol.176.12.7605","article-title":"Local amplification of glucocorticoids by 11 beta-hydroxysteroid dehydrogenase type 1 promotes macrophage phagocytosis of apoptotic leukocytes","volume":"176","author":"Gilmour","year":"2006","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.kint.2019.02.030_bib16","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nm1545","article-title":"Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity","volume":"13","author":"Leopold","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2019.02.030_bib17","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1161\/CIRCULATIONAHA.112.094722","article-title":"Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension","volume":"126","author":"Maron","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2019.02.030_bib18","first-page":"329","article-title":"Spironolactone inhibits NADPH oxidase-induced oxidative stress and enhances eNOS in human endothelial cells","volume":"10","author":"Taye","year":"2011","journal-title":"Iran J Pharm Res"},{"key":"10.1016\/j.kint.2019.02.030_bib19","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1161\/01.HYP.0000154365.30593.d3","article-title":"Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src","volume":"45","author":"Callera","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2019.02.030_bib20","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/01.HYP.0000255636.11931.a2","article-title":"Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1","volume":"49","author":"Shibata","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2019.02.030_bib21","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1681\/ASN.2005040390","article-title":"Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells","volume":"16","author":"Miyata","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.02.030_bib22","doi-asserted-by":"crossref","first-page":"F73","DOI":"10.1152\/ajprenal.00435.2007","article-title":"Aldosterone induces mesangial cell apoptosis both in\u00a0vivo and in\u00a0vitro","volume":"295","author":"Mathew","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2019.02.030_bib23","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1016\/j.yexcr.2008.09.018","article-title":"Aldosterone induces myofibroblastic transdifferentiation and collagen gene expression through the Rho-kinase dependent signaling pathway in rat mesangial cells","volume":"314","author":"Diah","year":"2008","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.kint.2019.02.030_bib24","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1006\/jmcc.1994.1098","article-title":"Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone","volume":"26","author":"Brilla","year":"1994","journal-title":"J\u00a0Mol Cell Cardiol"},{"key":"10.1016\/j.kint.2019.02.030_bib25","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/BF00226785","article-title":"Effects of angiotensin II and aldosterone on collagen gene expression and protein turnover in cardiac fibroblasts","volume":"154","author":"Zhou","year":"1996","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.kint.2019.02.030_bib26","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1161\/HYPERTENSIONAHA.107.102640","article-title":"Osteopontin in rat renal fibroblasts: functional properties and transcriptional regulation by aldosterone","volume":"51","author":"Irita","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2019.02.030_bib27","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1210\/jc.2003-031545","article-title":"Effect of aldosterone and glycyrrhetinic acid on the protein expression of PAI-1 and p22(phox) in human mononuclear leukocytes","volume":"89","author":"Calo","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2019.02.030_bib28","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.yjmcc.2017.12.011","article-title":"Neutrophil gelatinase-associated lipocalin from immune cells is mandatory for aldosterone-induced cardiac remodeling and inflammation","volume":"115","author":"Buonafine","year":"2018","journal-title":"J\u00a0Mol Cell Cardiol"},{"key":"10.1016\/j.kint.2019.02.030_bib29","doi-asserted-by":"crossref","first-page":"T83","DOI":"10.1530\/JOE-17-0155","article-title":"30 years of the mineralocorticoid receptor: mineralocorticoid receptor null mice: informing cell-type-specific roles","volume":"234","author":"Cole","year":"2017","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.kint.2019.02.030_bib30","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ejphar.2008.06.019","article-title":"Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats","volume":"589","author":"Taira","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.kint.2019.02.030_bib31","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.105.539122","article-title":"Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria","volume":"112","author":"Quinkler","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2019.02.030_bib32","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1161\/HYPERTENSIONAHA.109.148783","volume":"55","author":"Krug","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2019.02.030_bib33","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/10739680490266207","article-title":"Enhancement of glucocorticoid and mineralocorticoid receptor density in the microcirculation of the spontaneously hypertensive rat","volume":"11","author":"DeLano","year":"2004","journal-title":"Microcirculation"},{"key":"10.1016\/j.kint.2019.02.030_bib34","doi-asserted-by":"crossref","first-page":"T125","DOI":"10.1530\/JOE-16-0600","article-title":"30 years of the mineralocorticoid receptor: Mineralocorticoid receptor antagonists: 60 years of research and development","volume":"234","author":"Kolkhof","year":"2017","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.kint.2019.02.030_bib35","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/MNH.0000000000000147","article-title":"Nonsteroidal antagonists of the mineralocorticoid receptor","volume":"24","author":"Kolkhof","year":"2015","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.kint.2019.02.030_bib36","doi-asserted-by":"crossref","first-page":"F78","DOI":"10.1152\/ajprenal.00077.2007","article-title":"Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor\u00a0blocker spironolactone","volume":"293","author":"Mej\u00eda-Vilet","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2019.02.030_bib37","doi-asserted-by":"crossref","first-page":"F932","DOI":"10.1152\/ajprenal.00252.2009","article-title":"Adrenalectomy prevents renal ischemia-reperfusion injury","volume":"297","author":"Ramirez","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2019.02.030_bib38","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1093\/ndt\/gfs014","article-title":"Recovery from ischemic acute kidney injury by spironolactone administration","volume":"27","author":"Sanchez-Pozos","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2019.02.030_bib39","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1681\/ASN.2014121216","article-title":"Sulfenic acid modification of endothelin B receptor is responsible for the benefit of a nonsteroidal mineralocorticoid receptor antagonist in renal ischemia","volume":"27","author":"Barrera-Chimal","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.02.030_bib40","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/HYPERTENSIONAHA.116.08526","article-title":"Nonsteroidal mineralocorticoid receptor antagonist finerenone protects against acute kidney injury-mediated chronic kidney disease: role of oxidative stress","volume":"69","author":"Lattenist","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2019.02.030_bib41","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1681\/ASN.2016040477","article-title":"Benefit of mineralocorticoid receptor antagonism in AKI: role of vascular smooth muscle Rac1","volume":"28","author":"Barrera-Chimal","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.02.030_bib42","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jss.2014.04.040","article-title":"Pretreatment with mineralocorticoid receptor blocker reduces intestinal injury induced by ischemia and reperfusion: involvement of inhibition of inflammatory response, oxidative stress, nuclear factor kappaB, and inducible nitric oxide synthase","volume":"191","author":"Ozacmak","year":"2014","journal-title":"J\u00a0Surg Res"},{"key":"10.1016\/j.kint.2019.02.030_bib43","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1210\/en.2007-1770","article-title":"The role of mineralocorticoid receptor expression in brain remodeling after cerebral ischemia","volume":"149","author":"Oyamada","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.kint.2019.02.030_bib44","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1161\/01.RES.0000244092.95152.86","article-title":"Novel effect of mineralocorticoid receptor antagonism to reduce proinflammatory cytokines and hypothalamic activation in rats with ischemia-induced heart failure","volume":"99","author":"Kang","year":"2006","journal-title":"Circ Res"},{"key":"10.1016\/j.kint.2019.02.030_bib45","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000484962","article-title":"Acute kidney injury to chronic kidney disease transition","volume":"193","author":"Fiorentino","year":"2018","journal-title":"Contrib Nephrol"},{"key":"10.1016\/j.kint.2019.02.030_bib46","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/ki.2012.352","article-title":"Spironolactone prevents chronic kidney disease caused by ischemic acute kidney injury","volume":"83","author":"Barrera-Chimal","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.02.030_bib47","article-title":"Delayed spironolactone administration prevents the transition from acute kidney injury to chronic kidney disease through improving renal inflammation","author":"Barrera-Chimal","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2019.02.030_bib48","doi-asserted-by":"crossref","first-page":"892","DOI":"10.7150\/ijbs.11729","article-title":"Mild ischemic injury leads to long-term alterations in the kidney: amelioration by spironolactone administration","volume":"11","author":"Barrera-Chimal","year":"2015","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.kint.2019.02.030_bib49","doi-asserted-by":"crossref","first-page":"e002584","DOI":"10.1161\/JAHA.112.002584","article-title":"Myeloid mineralocorticoid receptor during experimental ischemic stroke: effects of model and sex","volume":"1","author":"Frieler","year":"2012","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.kint.2019.02.030_bib50","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1161\/STROKEAHA.110.598441","article-title":"Myeloid-specific deletion of the mineralocorticoid receptor reduces infarct volume and alters inflammation during cerebral ischemia","volume":"42","author":"Frieler","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.kint.2019.02.030_bib51","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1210\/en.2016-1040","article-title":"Cardiac tissue injury and remodeling is dependent upon MR regulation of activation pathways in cardiac tissue macrophages","volume":"157","author":"Shen","year":"2016","journal-title":"Endocrinology"},{"key":"10.1016\/j.kint.2019.02.030_bib52","doi-asserted-by":"crossref","first-page":"e110950","DOI":"10.1371\/journal.pone.0110950","article-title":"Myeloid mineralocorticoid receptor deficiency inhibits aortic constriction-induced cardiac hypertrophy in mice","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2019.02.030_bib53","doi-asserted-by":"crossref","first-page":"R879","DOI":"10.1152\/ajpregu.00075.2014","article-title":"Cardiac macrophages and apoptosis after myocardial infarction: effects of central MR blockade","volume":"307","author":"Rafatian","year":"2014","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.kint.2019.02.030_bib54","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1172\/JCI118867","article-title":"Role of aldosterone in the remnant kidney model in the rat","volume":"98","author":"Greene","year":"1996","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2019.02.030_bib55","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1681\/ASN.2004090804","article-title":"Regression of existing glomerulosclerosis by inhibition of aldosterone","volume":"16","author":"Aldigier","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.02.030_bib56","doi-asserted-by":"crossref","first-page":"7899","DOI":"10.1038\/s41598-017-08383-2","article-title":"A\u00a0novel aldosterone antagonist limits renal injury in 5\/6 nephrectomy","volume":"7","author":"Fujihara","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.kint.2019.02.030_bib57","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1161\/01.HYP.0000222003.28517.99","article-title":"Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker","volume":"47","author":"Nagase","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2019.02.030_bib58","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ejphar.2015.11.028","article-title":"CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats","volume":"769","author":"Arai","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.kint.2019.02.030_bib59","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/nm.1879","article-title":"Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease","volume":"14","author":"Shibata","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2019.02.030_bib60","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1291\/hypres.27.971","article-title":"Spironolactone in combination with cilazapril ameliorates proteinuria and renal interstitial fibrosis in rats with anti-Thy-1 irreversible nephritis","volume":"27","author":"Asai","year":"2004","journal-title":"Hypertens Res"},{"key":"10.1016\/j.kint.2019.02.030_bib61","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/08860220600779033","article-title":"Aldosterone blockage in proliferative glomerulonephritis prevents not only fibrosis, but proliferation as well","volume":"28","author":"Gullulu","year":"2006","journal-title":"Ren Fail"},{"key":"10.1016\/j.kint.2019.02.030_bib62","first-page":"199","article-title":"Aldosterone mediates glomerular inflammation in experimental mesangial proliferative glomerulonephritis","volume":"26","author":"Qin","year":"2013","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.kint.2019.02.030_bib63","first-page":"606","article-title":"The selective mineralocorticoid receptor antagonist eplerenone is protective in mild anti-GBM glomeru-lonephritis","volume":"4","author":"Zitt","year":"2011","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.kint.2019.02.030_bib64","doi-asserted-by":"crossref","first-page":"e0145666","DOI":"10.1371\/journal.pone.0145666","article-title":"Suppression of rapidly progressive mouse glomerulonephritis with the non-steroidal mineralocorticoid receptor antagonist BR-4628","volume":"10","author":"Ma","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2019.02.030_bib65","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.33.1.232","article-title":"Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats","volume":"33","author":"Rocha","year":"1999","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2019.02.030_bib66","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1046\/j.1523-1755.2000.00277.x","article-title":"Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in\u00a0vivo","volume":"58","author":"Brown","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.02.030_bib67","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000077396","article-title":"Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME\/SHR model","volume":"24","author":"Zhou","year":"2004","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2019.02.030_bib68","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/ki.2008.507","article-title":"Spironolactone suppresses inflammation and prevents L-NAME-induced renal injury in rats","volume":"75","author":"Ikeda","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.02.030_bib69","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1046\/j.1523-1755.2003.00929.x","article-title":"Aldosterone\/salt induces renal inflammation and fibrosis in hypertensive rats","volume":"63","author":"Blasi","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.02.030_bib70","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000335559","article-title":"Antihypertensive and cardiorenal protective effects of SM-368229, a novel mineralocorticoid receptor antagonist, in aldosterone\/salt-treated rats","volume":"89","author":"Nariai","year":"2012","journal-title":"Pharmacology"},{"key":"10.1016\/j.kint.2019.02.030_bib71","doi-asserted-by":"crossref","first-page":"e0193380","DOI":"10.1371\/journal.pone.0193380","article-title":"Preclinical pharmacology of AZD9977: a novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion","volume":"13","author":"Bamberg","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2019.02.030_bib72","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1124\/jpet.116.234765","article-title":"CS-3150, a novel nonsteroidal mineralocorticoid receptor antagonist, shows preventive and therapeutic effects on renal injury in deoxycorticosterone acetate\/salt-induced hypertensive rats","volume":"358","author":"Arai","year":"2016","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.kint.2019.02.030_bib73","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1161\/HYPERTENSIONAHA.115.06530","article-title":"Deoxycorticosterone acetate\/salt-induced cardiac but not renal injury is mediated by endothelial mineralocorticoid receptors independently from blood pressure","volume":"67","author":"Lother","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2019.02.030_bib74","first-page":"1590","article-title":"Prevention of renal fibrosis by spironolactone in mice with complete unilateral ureteral obstruction","volume":"172","author":"Trachtman","year":"2004","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.kint.2019.02.030_bib75","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1159\/000355736","article-title":"Eplerenone-mediated aldosterone blockade prevents renal fibrosis by reducing renal inflammation, interstitial cell proliferation and oxidative stress","volume":"37","author":"Chen","year":"2013","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.kint.2019.02.030_bib76","first-page":"328","article-title":"The inhibitory effect of eplerenone on cell proliferation in the contralateral kidneys of rats with unilateral ureteral obstruction","volume":"136","author":"Wang","year":"2017","journal-title":"Nephronology"},{"key":"10.1016\/j.kint.2019.02.030_bib77","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/20009666.2018.1500423","article-title":"Diabetic nephropathy: newer therapeutic perspectives","volume":"8","author":"Keri","year":"2018","journal-title":"J\u00a0Community Hosp Intern Med Perspect"},{"key":"10.1016\/j.kint.2019.02.030_bib78","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/j.1523-1755.2004.00913.x","article-title":"Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats","volume":"66","author":"Fujisawa","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.02.030_bib79","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1210\/en.2006-0944","article-title":"Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus","volume":"147","author":"Guo","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.kint.2019.02.030_bib80","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3317\/jraas.2007.014","article-title":"Beneficial effects of spironolactone on glomerular injury in streptozotocin-induced diabetic rats","volume":"8","author":"Yuan","year":"2007","journal-title":"J\u00a0Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.kint.2019.02.030_bib81","doi-asserted-by":"crossref","first-page":"e39938","DOI":"10.1371\/journal.pone.0039938","article-title":"Aldosterone antagonists in monotherapy are protective against streptozotocin-induced diabetic nephropathy in rats","volume":"7","author":"Banki","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2019.02.030_bib82","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/ndt\/gfr495","article-title":"Long-term mineralocorticoid receptor blockade ameliorates progression of experimental diabetic renal disease","volume":"27","author":"Lian","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2019.02.030_bib83","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/1470320311422581","article-title":"Spironolactone improves nephropathy by enhancing glucose-6-phosphate dehydrogenase activity and reducing oxidative stress in diabetic hypertensive rat","volume":"13","author":"Pessoa","year":"2012","journal-title":"J\u00a0Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.kint.2019.02.030_bib84","first-page":"1339","article-title":"An additive effect of eplerenone to ACE inhibitor on slowing the progression of diabetic nephropathy in the db\/db mice","volume":"8","author":"Zhou","year":"2016","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.kint.2019.02.030_bib85","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1681\/ASN.2005111196","article-title":"Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats","volume":"17","author":"Han","year":"2006","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.02.030_bib86","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/ndt\/gfn448","article-title":"Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats","volume":"24","author":"Kang","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2019.02.030_bib87","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1124\/jpet.109.158113","article-title":"Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats","volume":"332","author":"Nishiyama","year":"2010","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.kint.2019.02.030_bib88","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1111\/dom.13393","article-title":"Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction","volume":"20","author":"Lachaux","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.kint.2019.02.030_bib89","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1161\/HYPERTENSIONAHA.107.091058","article-title":"Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress","volume":"50","author":"Nagase","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2019.02.030_bib90","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/ijo.2011.232","article-title":"Role of mineralocorticoid receptor\/Rho\/Rho-kinase pathway in obesity-related renal injury","volume":"36","author":"Tokuyama","year":"2012","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.kint.2019.02.030_bib91","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000358758","article-title":"Local mineralocorticoid receptor activation and the role of Rac1 in obesity-related diabetic kidney disease","volume":"126","author":"Yoshida","year":"2014","journal-title":"Nephron Exp Nephrol"},{"key":"10.1016\/j.kint.2019.02.030_bib92","doi-asserted-by":"crossref","first-page":"F2","DOI":"10.1152\/ajprenal.00072.2007","article-title":"New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone","volume":"293","author":"Bobadilla","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2019.02.030_bib93","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/0006-2952(87)90721-0","article-title":"The influence of enalapril or spironolactone on experimental cyclosporin nephrotoxicity","volume":"36","author":"McAuley","year":"1987","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.kint.2019.02.030_bib94","doi-asserted-by":"crossref","first-page":"F1020","DOI":"10.1152\/ajprenal.00166.2005","article-title":"Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity","volume":"289","author":"P\u00e9rez-Rojas","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2019.02.030_bib95","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1093\/ndt\/gfn204","article-title":"Inhibition of mineralocorticoid receptors with eplerenone alleviates short-term cyclosporin A nephrotoxicity in conscious rats","volume":"23","author":"Nielsen","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2019.02.030_bib96","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/ki.2015.312","article-title":"Deletion of mineralocorticoid receptors in smooth muscle cells blunts renal vascular resistance following acute cyclosporine administration","volume":"89","author":"Amador","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.02.030_bib97","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1046\/j.1523-1755.2003.00707.x","article-title":"Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity","volume":"63","author":"Feria","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.02.030_bib98","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1471-2369-14-42","article-title":"The mineralocorticoid receptor antagonist eplerenone reduces renal interstitial fibrosis after long-term cyclosporine treatment in rat: antagonizing cyclosporine nephrotoxicity","volume":"14","author":"Nielsen","year":"2013","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2019.02.030_bib99","doi-asserted-by":"crossref","first-page":"F131","DOI":"10.1152\/ajprenal.00147.2006","article-title":"Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity","volume":"292","author":"P\u00e9rez-Rojas","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2019.02.030_bib100","doi-asserted-by":"crossref","first-page":"F1072","DOI":"10.1152\/ajprenal.90643.2008","article-title":"Spironolactone ameliorates transplant vasculopathy in renal chronic transplant dysfunction in rats","volume":"296","author":"Waanders","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2019.02.030_bib101","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1159\/000339649","article-title":"Mineralocorticoid receptor antagonism and aldosterone synthesis inhibition do not improve glomerulosclerosis and renal interstitial fibrosis in a model of chronic kidney allograft injury","volume":"35","author":"Lahmer","year":"2012","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.kint.2019.02.030_bib102","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1161\/HYPERTENSIONAHA.107.109645","article-title":"Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats","volume":"52","author":"Michea","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2019.02.030_bib103","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.yjmcc.2018.06.008","article-title":"Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice","volume":"121","author":"Bonnard","year":"2018","journal-title":"J\u00a0Mol Cell Cardiol"},{"key":"10.1016\/j.kint.2019.02.030_bib104","doi-asserted-by":"crossref","first-page":"H1126","DOI":"10.1152\/ajpheart.00898.2014","article-title":"Mineralocorticoid receptor blockade prevents Western diet-induced diastolic dysfunction in female mice","volume":"308","author":"Bostick","year":"2015","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.kint.2019.02.030_bib105","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1161\/CIRCRESAHA.115.308269","article-title":"Endothelial mineralocorticoid receptor mediates diet-induced aortic stiffness in females","volume":"118","author":"Jia","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.kint.2019.02.030_bib106","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1463-1326.2011.01499.x","article-title":"Protective effects of mineralocorticoid receptor blockade against neuropathy in experimental diabetic rats","volume":"14","author":"Takata","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.kint.2019.02.030_bib107","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1096\/fj.10-173286","article-title":"Mineralocorticoid receptor-mediated DNA damage in kidneys of DOCA-salt hypertensive rats","volume":"25","author":"Schupp","year":"2011","journal-title":"FASEB J"},{"key":"10.1016\/j.kint.2019.02.030_bib108","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1161\/01.HYP.0000118519.66430.22","article-title":"Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone\/salt-induced hypertensive rats","volume":"43","author":"Nishiyama","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2019.02.030_bib109","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1161\/01.CIR.0000127949.05756.9D","article-title":"Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone","volume":"109","author":"Keidar","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2019.02.030_bib110","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1210\/en.2007-0864","article-title":"Aldosterone induces superoxide generation via Rac1 activation in endothelial cells","volume":"149","author":"Iwashima","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.kint.2019.02.030_bib111","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10741-005-2348-y","article-title":"The mineralocorticoid receptor and oxidative stress","volume":"10","author":"Fiebeler","year":"2005","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.kint.2019.02.030_bib112","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.cardiores.2007.07.008","article-title":"Cross-talk between aldosterone and angiotensin II in vascular smooth muscle cell senescence","volume":"76","author":"Min","year":"2007","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.kint.2019.02.030_bib113","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/nm.2891","article-title":"Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors","volume":"18","author":"McCurley","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2019.02.030_bib114","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1097\/HJH.0000000000000284","article-title":"Oxidative stress in patients affected by primary aldosteronism","volume":"32","author":"Petramala","year":"2014","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.kint.2019.02.030_bib115","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1159\/000350539","article-title":"Mineralocorticoid receptor blockade reduced oxidative stress in renal transplant recipients: a double-blind, randomized pilot study","volume":"37","author":"Ojeda-Cervantes","year":"2013","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2019.02.030_bib116","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1210\/jc.2005-1718","article-title":"Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy","volume":"91","author":"Takebayashi","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2019.02.030_bib117","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1254\/jphs.SC0060049","article-title":"Anti-inflammatory effect of spironolactone on human peripheral blood mononuclear cells","volume":"101","author":"Miura","year":"2006","journal-title":"J\u00a0Pharmacol Sci"},{"key":"10.1016\/j.kint.2019.02.030_bib118","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.3389\/fimmu.2017.01319","article-title":"Deletion of the mineralocorticoid receptor in myeloid cells attenuates central nervous system autoimmunity","volume":"8","author":"Montes-Cobos","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2019.02.030_bib119","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1161\/ATVBAHA.115.307031","article-title":"Mineralocorticoid receptor deficiency in macrophages inhibits neointimal hyperplasia and suppresses macrophage inflammation through SGK1-AP1\/NF-kappaB pathways","volume":"36","author":"Sun","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.kint.2019.02.030_bib120","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1161\/HYPERTENSIONAHA.113.02883","article-title":"Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes","volume":"63","author":"Amador","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2019.02.030_bib121","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4049\/jimmunol.0802886","article-title":"Aldosterone promotes autoimmune damage by enhancing Th17-mediated immunity","volume":"184","author":"Herrada","year":"2010","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.kint.2019.02.030_bib122","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1161\/01.HYP.35.5.1078","article-title":"Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats","volume":"35","author":"Sun","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2019.02.030_bib123","doi-asserted-by":"crossref","first-page":"e0145946","DOI":"10.1371\/journal.pone.0145946","article-title":"Aldosterone induces renal fibrosis and inflammatory M1-macrophage subtype via mineralocorticoid receptor in rats","volume":"11","author":"Martin-Fernandez","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2019.02.030_bib124","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.gene.2013.08.047","article-title":"Aldosterone stimulates fibronectin synthesis in renal fibroblasts through mineralocorticoid receptor-dependent and independent mechanisms","volume":"531","author":"Chen","year":"2013","journal-title":"Gene"},{"key":"10.1016\/j.kint.2019.02.030_bib125","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.amjhyper.2005.08.019","article-title":"Plasma osteopontin levels are higher in patients with primary aldosteronism than in patients with essential hypertension","volume":"19","author":"Irita","year":"2006","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.kint.2019.02.030_bib126","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1159\/000339500","article-title":"Aldosterone induces kidney fibroblast proliferation via activation of growth factor receptors and PI3K\/MAPK signalling","volume":"120","author":"Huang","year":"2012","journal-title":"Nephron Exp Nephrol"},{"key":"10.1016\/j.kint.2019.02.030_bib127","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1161\/HYPERTENSIONAHA.113.01967","article-title":"Smooth muscle cell mineralocorticoid receptors are mandatory for aldosterone-salt to induce vascular stiffness","volume":"63","author":"Galmiche","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2019.02.030_bib128","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/ATVBAHA.112.300569","article-title":"Galectin-3 mediates aldosterone-induced vascular fibrosis","volume":"33","author":"Calvier","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.kint.2019.02.030_bib129","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/ATVBAHA.113.302854","article-title":"Aldosterone promotes vascular remodeling by direct effects on smooth muscle cell mineralocorticoid receptors","volume":"34","author":"Pruthi","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.kint.2019.02.030_bib130","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1161\/HYPERTENSIONAHA.115.05431","article-title":"Neutrophil gelatinase-associated lipocalin, a novel mineralocorticoid biotarget, mediates vascular profibrotic effects of mineralocorticoids","volume":"66","author":"Tarjus","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2019.02.030_bib131","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1161\/HYPERTENSIONAHA.117.09791","article-title":"Aldosterone target NGAL (neutrophil gelatinase-associated lipocalin) is involved in cardiac remodeling after myocardial infarction through NFkappaB pathway","volume":"70","author":"Martinez-Martinez","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2019.02.030_bib132","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jchf.2014.08.002","article-title":"The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries","volume":"3","author":"Calvier","year":"2015","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.kint.2019.02.030_bib133","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000368267","article-title":"Mineralocorticoid and SGK1-sensitive inflammation and tissue fibrosis","volume":"128","author":"Artunc","year":"2014","journal-title":"Nephron Physiol"},{"key":"10.1016\/j.kint.2019.02.030_bib134","doi-asserted-by":"crossref","first-page":"43060","DOI":"10.1074\/jbc.M308134200","article-title":"Aldosterone stimulates epidermal growth factor receptor expression","volume":"278","author":"Krug","year":"2003","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kint.2019.02.030_bib135","first-page":"CD007004","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease","author":"Bolignano","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.kint.2019.02.030_bib136","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12882-016-0337-0","article-title":"Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis","volume":"17","author":"Currie","year":"2016","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2019.02.030_bib137","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.clinthera.2015.05.508","article-title":"Spironolactone add-on for preventing or slowing the progression of diabetic nephropathy: a meta-analysis","volume":"37","author":"Hou","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.kint.2019.02.030_bib138","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2019.02.030_bib139","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","article-title":"Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease","volume":"70","author":"Bianchi","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.02.030_bib140","doi-asserted-by":"crossref","first-page":"e26904","DOI":"10.1371\/journal.pone.0026904","article-title":"Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study","volume":"6","author":"Boesby","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2019.02.030_bib141","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1681\/ASN.2014070688","article-title":"Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis","volume":"26","author":"Heerspink","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.02.030_bib142","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1038\/ki.2015.301","article-title":"Proteinuria as a surrogate marker for renal outcome: Are we there yet?","volume":"88","author":"Avasare","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.02.030_bib143","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1053\/j.ajkd.2009.04.029","article-title":"Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration","volume":"54","author":"Levey","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2019.02.030_bib144","author":"US Food and Drug Administration"},{"key":"10.1016\/j.kint.2019.02.030_bib145","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ekir.2017.04.001","article-title":"Exploring novel endpoints for clinical trials in kidney disease: challenges and opportunities","volume":"2","author":"Roy-Chaudhury","year":"2017","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2019.02.030_bib146","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/01.ASN.0000100125.21491.46","article-title":"The number, quality, and coverage of randomized controlled trials in nephrology","volume":"15","author":"Strippoli","year":"2004","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.02.030_bib147","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","article-title":"GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration","volume":"64","author":"Levey","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2019.02.030_bib148","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1093\/eurheartj\/ehs257","article-title":"Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice","volume":"33","author":"Zannad","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.kint.2019.02.030_bib149","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.kint.2019.02.030_bib150","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/ejhf.621","article-title":"A\u00a0tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis","volume":"18","author":"Girerd","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.kint.2019.02.030_bib151","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.jacc.2013.04.086","article-title":"Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and\/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (eplerenone in mild patients hospitalization and survival study in heart failure)","volume":"62","author":"Eschalier","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.kint.2019.02.030_bib152","article-title":"Association between mineralocorticoid receptor antagonist use and outcome in myocardial\u00a0infarction patients with heart failure","volume":"7","author":"L\u00f6fman","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.kint.2019.02.030_bib153","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney\u00a0disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.kint.2019.02.030_bib154","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jacc.2009.03.066","article-title":"Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney\u00a0disease: a randomized controlled trial","volume":"54","author":"Edwards","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.kint.2019.02.030_bib155","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.amjcard.2010.07.018","article-title":"Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease","volume":"106","author":"Edwards","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.kint.2019.02.030_bib156","doi-asserted-by":"crossref","first-page":"e64549","DOI":"10.1371\/journal.pone.0064549","article-title":"Eplerenone attenuates pulse wave reflection in chronic kidney disease stage 3-4--a randomized controlled study","volume":"8","author":"Boesby","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2019.02.030_bib157","doi-asserted-by":"crossref","first-page":"T67","DOI":"10.1530\/JOE-17-0009","article-title":"30 years of the mineralocorticoid receptor: the role of the mineralocorticoid receptor in the vasculature","volume":"234","author":"DuPont","year":"2017","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.kint.2019.02.030_bib158","first-page":"392","article-title":"Spironolactone in chronic hemodialysis patients improves cardiac function","volume":"20","author":"Taheri","year":"2009","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"10.1016\/j.kint.2019.02.030_bib159","first-page":"507","article-title":"A\u00a0prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis","volume":"23","author":"Taheri","year":"2012","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"10.1016\/j.kint.2019.02.030_bib160","first-page":"199","article-title":"Left ventricular dysfunction in the haemodialysis population","volume":"1","author":"Sood","year":"2008","journal-title":"NDT Plus"},{"key":"10.1016\/j.kint.2019.02.030_bib161","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.kint.2018.11.025","article-title":"A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients","volume":"95","author":"Hammer","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.02.030_bib162","article-title":"Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial","author":"Charytan","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.02.030_bib163","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1053\/j.ajkd.2016.04.011","article-title":"The safety and efficacy of mineralocorticoid receptor antagonists in patients who require dialysis: a systematic review and meta-analysis","volume":"68","author":"Quach","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2019.02.030_bib164","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/1745-6215-15-160","volume":"15","author":"Hill","year":"2014","journal-title":"Trials"},{"key":"10.1016\/j.kint.2019.02.030_bib165","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/1745-6215-15-158","article-title":"Spironolactone to prevent cardiovascular events in early-stage chronic kidney disease (STOP-CKD): study protocol for a randomized controlled pilot trial","volume":"15","author":"Ng","year":"2014","journal-title":"Trials"},{"key":"10.1016\/j.kint.2019.02.030_bib166","doi-asserted-by":"crossref","first-page":"e010519","DOI":"10.1136\/bmjopen-2015-010519","article-title":"Results and lessons from the Spironolactone To Prevent Cardiovascular Events in Early Stage Chronic Kidney Disease (STOP-CKD) randomised controlled trial","volume":"6","author":"Ng","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.kint.2019.02.030_bib167","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1186\/s13063-018-2956-1","article-title":"EPURE Transplant (Eplerenone in Patients Undergoing Renal Transplant) Study: study protocol for a randomized controlled trial","volume":"19","author":"Girerd","year":"2018","journal-title":"Trials"},{"key":"10.1016\/j.kint.2019.02.030_bib168","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.2215\/CJN.05300516","article-title":"Randomized controlled trial of mineralocorticoid receptor blockade in children with chronic kidney allograft nephropathy","volume":"12","author":"Medeiros","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.02.030_bib169","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12882-018-0885-6","article-title":"The effect of spironolactone on calcineurin inhibitor induced nephrotoxicity: a multicenter randomized, double-blind, clinical trial (the SPIREN trial)","volume":"19","author":"Mortensen","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2019.02.030_bib170","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1053\/j.ajkd.2016.06.013","article-title":"The effect of spironolactone on acute kidney injury after cardiac surgery: a randomized, placebo-controlled trial","volume":"69","author":"Barba-Navarro","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2019.02.030_bib171","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1097\/CCM.0b013e31825b8be2","article-title":"Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery","volume":"40","author":"Pretorius","year":"2012","journal-title":"Crit Care Med"},{"key":"10.1016\/j.kint.2019.02.030_bib172","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40119-018-0112-3","article-title":"The effect of spironolactone on the incidence of contrast-induced nephropathy in patients undergoing cardiac catheterization: study design and rationale","volume":"7","author":"Mujtaba","year":"2018","journal-title":"Cardiol Ther"},{"key":"10.1016\/j.kint.2019.02.030_bib173","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","article-title":"The incidence and implications of aldosterone breakthrough","volume":"3","author":"Bomback","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.kint.2019.02.030_bib174","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","article-title":"Effectiveness of aldosterone blockade in patients with diabetic nephropathy","volume":"41","author":"Sato","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2019.02.030_bib175","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","article-title":"Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate","volume":"47","author":"Schjoedt","year":"2004","journal-title":"Diabetologia"},{"key":"10.1016\/j.kint.2019.02.030_bib176","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/ki.2008.204","article-title":"Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy","volume":"74","author":"Bakris","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.02.030_bib177","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.2215\/CJN.06960712","article-title":"Determinants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy","volume":"8","author":"Moranne","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.02.030_bib178","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1093\/ndt\/gft281","article-title":"Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial","volume":"28","author":"Esteghamati","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2019.02.030_bib179","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/eurjhf\/hft134","article-title":"Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.kint.2019.02.030_bib180","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.kint.2019.02.030_bib181","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jacc.2016.06.060","article-title":"Hyperkalemia in heart failure","volume":"68","author":"Sarwar","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.kint.2019.02.030_bib182","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ahj.2017.03.011","article-title":"True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: a meta-analysis","volume":"188","author":"Vukadinovic","year":"2017","journal-title":"Am Heart J"},{"key":"10.1016\/j.kint.2019.02.030_bib183","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1016\/j.transproceed.2010.08.024","article-title":"Addition of spironolactone to dual blockade of renin angiotensin system dramatically reduces severe proteinuria in renal transplant patients: an uncontrolled pilot study at 6 months","volume":"42","author":"Gonzalez Monte","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1016\/j.kint.2019.02.030_bib184","doi-asserted-by":"crossref","first-page":"e0153635","DOI":"10.1371\/journal.pone.0153635","article-title":"Safety of eplerenone for kidney-transplant recipients with impaired renal function and receiving cyclosporine A","volume":"11","author":"Bertocchio","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2019.02.030_bib185","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ejhf.1199","article-title":"Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists","volume":"20","author":"Trevisan","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.kint.2019.02.030_bib186","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.116.002946","article-title":"Characterization of mineralocorticoid receptor antagonist therapy initiation in high-risk patients with heart failure","volume":"10","author":"Cooper","year":"2017","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.kint.2019.02.030_bib187","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/nrneph.2012.217","article-title":"Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy","volume":"8","author":"Roscioni","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2019.02.030_bib188","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"Weir","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2019.02.030_bib189","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/ehf2.12292","article-title":"Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes\/angiotensin receptor blockers: results from AMETHYST-DN","volume":"5","author":"Pitt","year":"2018","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.kint.2019.02.030_bib190","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.kint.2017.08.038","article-title":"Revisiting RAAS blockade in CKD with newer potassium-binding drugs","volume":"93","author":"Georgianos","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.02.030_bib191","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1411487","article-title":"Sodium zirconium cyclosilicate in hyperkalemia","volume":"372","author":"Packham","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2019.02.030_bib192","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1001\/jama.2014.15688","article-title":"Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial","volume":"312","author":"Kosiborod","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2019.02.030_bib193","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/HYPERTENSIONAHA.115.04889","article-title":"New potassium binders for the treatment of hyperkalemia: current data and opportunities for the future","volume":"66","author":"Pitt","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2019.02.030_bib194","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.kint.2019.02.030_bib195","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3389\/fphar.2013.00115","article-title":"PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy","volume":"4","author":"Orena","year":"2013","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.kint.2019.02.030_bib196","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1517\/13543784.2015.1059819","article-title":"Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease","volume":"24","author":"Liu","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.kint.2019.02.030_bib197","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/164_2016_76","article-title":"Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside","volume":"243","author":"Kolkhof","year":"2017","journal-title":"Handb Exp Pharmacol"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S008525381930300X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S008525381930300X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:52:52Z","timestamp":1758761572000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S008525381930300X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":197,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S008525381930300X"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2019.02.030","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2019.02.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}